Oxford Cannabinoid Technologies Holdings PLC’s (LSE:OCTP) John Lucas talks to Proactive London about their pipeline of cannabis-derived pharmaceutical treatments for pain relief.
The firm expect to report financial results in line with expectations as it updated on the progress of its drug pipeline.
It spent £920,000 on research and development in the six months to the end of November. A total of £604,000 was invested in lead candidate OCT461201 for neuropathic and visceral pain. As at the end of the first half, the company was well-financed with £12mln in the bank.
To understand more about the investment case for the firm, you can view a research analyst piece here: https://youtu.be/5E3fQdwtTCU
source
